Revance Therapeutics, Inc.
RVNC · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $137 | $109 | $111 | $334 |
| Short-Term Investments | $117 | $232 | $114 | $103 |
| Receivables | $28 | $11 | $3 | $2 |
| Inventory | $46 | $18 | $10 | $6 |
| Other Curr. Assets | $12 | $4 | $8 | $6 |
| Total Curr. Assets | $339 | $375 | $246 | $450 |
| Property Plant & Equip (Net) | $90 | $68 | $69 | $47 |
| Goodwill | $0 | $77 | $147 | $147 |
| Intangibles | $10 | $27 | $55 | $71 |
| Long-Term Investments | $7 | $6 | $5 | $3 |
| Tax Assets | $0 | -$6 | -$5 | -$3 |
| Other NC Assets | $33 | $35 | $14 | $5 |
| Total NC Assets | $140 | $207 | $285 | $270 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $478 | $582 | $531 | $720 |
| Liabilities | – | – | – | – |
| Payables | $14 | $5 | $11 | $13 |
| Short-Term Debt | $11 | $5 | $5 | $9 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $11 | $7 | $9 | $8 |
| Other Curr. Liab. | $54 | $59 | $43 | $32 |
| Total Curr. Liab. | $89 | $76 | $67 | $61 |
| LT Debt | $468 | $414 | $320 | $27 |
| Deferred Rev, NC | $70 | $79 | $74 | $77 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $181 |
| Other NC Liab. | $3 | $1 | $1 | $0 |
| Total NC Liab. | $541 | $494 | $395 | $285 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $49 | $39 | $44 | $32 |
| Total Liabilities | $630 | $569 | $463 | $346 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$2,078 | -$1,754 | -$1,398 | -$1,126 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $1,927 | $1,767 | $1,466 | $1,501 |
| Total Equity | -$152 | $13 | $68 | $374 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $478 | $582 | $531 | $720 |
| Net Debt | $341 | $310 | $214 | -$298 |